MX2017011182A - Analogos de amilina. - Google Patents

Analogos de amilina.

Info

Publication number
MX2017011182A
MX2017011182A MX2017011182A MX2017011182A MX2017011182A MX 2017011182 A MX2017011182 A MX 2017011182A MX 2017011182 A MX2017011182 A MX 2017011182A MX 2017011182 A MX2017011182 A MX 2017011182A MX 2017011182 A MX2017011182 A MX 2017011182A
Authority
MX
Mexico
Prior art keywords
analogues
amylin analogues
diseases
amylin
diabetes
Prior art date
Application number
MX2017011182A
Other languages
English (en)
Inventor
Dieter Wolfgang Hamprecht
Rasmus Just
Lise Giehm
Alexandrovna Deryabina Maria
Demmer Oliver
Sloth Villadsen Jesper
Skarbaliene Jolanta
Mosolff Mathiesen Jesper
Kofoed Munch Henrik
Original Assignee
Zealand Pharma As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52779493&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2017011182(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Zealand Pharma As filed Critical Zealand Pharma As
Publication of MX2017011182A publication Critical patent/MX2017011182A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Abstract

La presente invención se refiere a análogos de amilina y a su uso en el tratamiento o la prevención de varias enfermedades, afecciones o trastornos, incluyendo obesidad, consumo excesivo de alimentos y enfermedades metabólicas asociadas tales como diabetes. Los análogos tienen una buena estabilidad física y química, una buena solubilidad y una larga duración de acción, y son adecuados para su uso en forma de una formulación líquida.
MX2017011182A 2015-03-18 2016-03-17 Analogos de amilina. MX2017011182A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP15159737 2015-03-18
PCT/EP2016/055793 WO2016146739A1 (en) 2015-03-18 2016-03-17 Amylin analogues

Publications (1)

Publication Number Publication Date
MX2017011182A true MX2017011182A (es) 2018-06-06

Family

ID=52779493

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017011182A MX2017011182A (es) 2015-03-18 2016-03-17 Analogos de amilina.

Country Status (19)

Country Link
US (2) US10766939B2 (es)
EP (1) EP3271381B1 (es)
JP (1) JP6769984B2 (es)
KR (1) KR20170126504A (es)
CN (1) CN107567459B (es)
AR (1) AR103954A1 (es)
AU (1) AU2016232218B2 (es)
BR (1) BR112017019378A2 (es)
CA (1) CA2979950A1 (es)
CL (1) CL2017002256A1 (es)
CO (1) CO2017008870A2 (es)
EA (1) EA035791B1 (es)
IL (1) IL253924A0 (es)
MX (1) MX2017011182A (es)
PE (1) PE20180497A1 (es)
PH (1) PH12017501674A1 (es)
SG (1) SG11201707286UA (es)
TW (1) TW201706294A (es)
WO (1) WO2016146739A1 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20180497A1 (es) 2015-03-18 2018-03-09 Zealand Pharma As Analogos de amilina
TWI784968B (zh) 2016-09-09 2022-12-01 丹麥商西蘭製藥公司 澱粉素類似物
PE20221168A1 (es) 2019-11-11 2022-07-25 Boehringer Ingelheim Int Agonistas del receptor npy2
JP2023522944A (ja) * 2020-04-20 2023-06-01 アイツーオー・セラピューティクス・インコーポレイテッド １型糖尿病患者に優れた血糖制御をもたらすためのヒトアミリンアナログポリペプチドの使用
CR20230074A (es) 2020-08-07 2023-04-19 Boehringer Ingelheim Int Agonistas del receptor npy2 solubles
PL4021929T3 (pl) 2020-09-24 2023-07-31 Gubra Aps Analogi ham15-52 z poprawioną si‎łą działania receptora amyliny (hamy3r)
WO2022248419A2 (en) 2021-05-22 2022-12-01 Adocia Compositions comprising short-acting hormones for treating or preventing obesity and pumps comprising said composition
EP4144362A1 (en) 2021-09-06 2023-03-08 Adocia Compositions comprising short-acting hormones for treating or preventing obesity and pumps comprising said composition
EP4129324A1 (en) 2021-08-02 2023-02-08 Adocia Compositions comprising at least an amylin receptor agonist and a glp-1 receptor agonist
CN113893349B (zh) * 2021-12-13 2022-07-22 北京大学第三医院（北京大学第三临床医学院） 达格列净及其类似物在制备防治雄性生殖功能障碍的药物中的用途
WO2023227133A1 (zh) * 2022-05-27 2023-11-30 杭州先为达生物科技股份有限公司 人胰淀素类似物、其衍生物及用途
WO2023232781A1 (en) * 2022-05-30 2023-12-07 Zealand Pharma A/S Liquid formulations of amylin analogues
WO2024022465A1 (zh) * 2022-07-29 2024-02-01 杭州九源基因工程有限公司 一种人胰淀素多肽衍生物及其用途

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5175146A (en) 1989-12-05 1992-12-29 Vical, Inc. Synthetic calcitonin peptides
US5234906A (en) 1991-01-10 1993-08-10 Amylin Pharmaceuticals, Inc. Hyperglycemic compositions
SK88793A3 (en) * 1991-11-19 1994-12-07 Amylin Pharmaceuticals Inc Amylin agonising peptides and their using
KR100429966B1 (ko) 1993-09-07 2004-05-04 아밀린 파마슈티칼스, 인크. 위장 운동성 조절을 위한 제약 조성물
DE69737479T4 (de) 1996-08-30 2010-05-06 Novo Nordisk A/S Glp-1 derivate
DE69732640T2 (de) 1996-09-09 2006-01-12 Zealand Pharma A/S Festphasen-peptidsynthese
US5677279A (en) 1996-12-16 1997-10-14 Amylin Pharmaceuticals, Inc. Methods and compositions for treating pain with amylin or agonists thereof
US7101853B2 (en) 1997-05-06 2006-09-05 Amylin Pharmaceuticals, Inc. Method for treating or preventing gastritis using amylin or amylin agonists
US7910548B2 (en) 1997-06-06 2011-03-22 Amylin Pharmaceuticals, Inc. Methods for treating obesity
WO1999034764A2 (en) 1998-01-09 1999-07-15 Amylin Pharmaceuticals, Inc. Amylin agonist pharmaceutical compositions containing insulin
US6451987B1 (en) 1999-03-15 2002-09-17 Novo Nordisk A/S Ion exchange chromatography of proteins and peptides
EP1956000B1 (en) 1999-03-17 2016-10-05 Novo Nordisk A/S Acylating agents useful for acylating peptides
ES2425221T3 (es) 2003-05-30 2013-10-14 Amylin Pharmaceuticals, Llc Nuevos métodos y composiciones para suministro por vía transmucosa potenciado de péptidos y proteínas
CA2849552A1 (en) 2004-02-11 2005-08-25 Amylin Pharmaceuticals, Llc Hybrid polypeptides with selectable properties
WO2006083254A1 (en) 2004-02-11 2006-08-10 Amylin Pharmaceuticals, Inc. Amylin family peptides and methods for making and using them
DE102004051014A1 (de) 2004-10-20 2006-04-27 Rwth Aachen Chemisch modifizierte Peptidanaloga
EP1922336B1 (en) 2005-08-11 2012-11-21 Amylin Pharmaceuticals, LLC Hybrid polypeptides with selectable properties
WO2007104789A2 (en) 2006-03-15 2007-09-20 Novo Nordisk A/S Amylin derivatives
AU2008216265B2 (en) 2007-02-15 2014-04-03 Indiana University Research And Technology Corporation Glucagon/GLP-1 receptor co-agonists
JP5385266B2 (ja) 2007-06-15 2014-01-08 ジーランド ファーマ アクティーゼルスカブ グルカゴン類似体
EP2036539A1 (en) 2007-09-11 2009-03-18 Novo Nordisk A/S Stable formulations of amylin and its analogues
EP2036923A1 (en) 2007-09-11 2009-03-18 Novo Nordisk A/S Improved derivates of amylin
EP2340261B1 (en) 2008-10-21 2017-12-20 Novo Nordisk A/S Amylin derivatives
DK2370462T3 (da) 2008-12-15 2014-09-08 Zealand Pharma As Glucagon-analoger
UA104605C2 (uk) 2008-12-15 2014-02-25 Зіленд Фарма А/С Аналоги глюкагону
ES2477880T3 (es) 2008-12-15 2014-07-18 Zealand Pharma A/S Análogos del glucagón
MX2011006320A (es) 2008-12-15 2011-09-22 Zealand Pharma As Analogos de glucagon.
US8748375B2 (en) 2009-03-17 2014-06-10 Amylin Pharmaceuticals, Llc Methods for affecting body composition using amylin agonists
DK2454282T3 (en) 2009-07-13 2015-05-04 Zealand Pharma As acetylated glucagonanaloger
CN102639559B (zh) 2009-11-25 2015-04-29 诺沃—诺迪斯克有限公司 用于制备多肽的方法
UY33462A (es) 2010-06-23 2012-01-31 Zealand Pharma As Analogos de glucagon
WO2011160633A1 (en) 2010-06-24 2011-12-29 Zealand Pharma A/S Glucagon analogues
EP2718316B1 (en) * 2011-06-10 2019-12-04 Novo Nordisk A/S Polypeptides
PE20142113A1 (es) 2011-12-23 2014-12-03 Zealand Pharma As Analogos de glucagon
US8575091B1 (en) 2012-04-19 2013-11-05 Novo Nordisk A/S Amylin analogues and pharmaceutical compositions thereof
PL2838914T3 (pl) * 2012-04-19 2017-11-30 Novo Nordisk A/S Analogi ludzkiej amyliny
TWI608013B (zh) 2012-09-17 2017-12-11 西蘭製藥公司 升糖素類似物
AR097701A1 (es) * 2013-09-19 2016-04-13 Zealand Pharma As Análogos de amilina
JP2016208556A (ja) * 2013-10-03 2016-12-08 三菱電機株式会社 デマンド予測装置及びデマンド予測方法
US10072060B2 (en) 2014-05-02 2018-09-11 The Research Foundation For The State University Of New York Islet amyloid polypeptides with improved solubility
CN106687474A (zh) 2014-09-04 2017-05-17 诺和诺德股份有限公司 新型胰淀素和降钙素受体激动剂
PE20180497A1 (es) 2015-03-18 2018-03-09 Zealand Pharma As Analogos de amilina
TWI784968B (zh) 2016-09-09 2022-12-01 丹麥商西蘭製藥公司 澱粉素類似物

Also Published As

Publication number Publication date
CN107567459A (zh) 2018-01-09
AU2016232218B2 (en) 2020-09-10
US10766939B2 (en) 2020-09-08
KR20170126504A (ko) 2017-11-17
EP3271381B1 (en) 2021-09-08
IL253924A0 (en) 2017-10-31
BR112017019378A2 (pt) 2019-02-19
TW201706294A (zh) 2017-02-16
EA035791B1 (ru) 2020-08-11
CO2017008870A2 (es) 2017-11-10
EA201791617A1 (ru) 2018-02-28
PH12017501674A1 (en) 2018-03-12
AR103954A1 (es) 2017-06-14
JP6769984B2 (ja) 2020-10-14
AU2016232218A1 (en) 2017-09-21
SG11201707286UA (en) 2017-10-30
CL2017002256A1 (es) 2018-04-02
US20160272693A1 (en) 2016-09-22
EP3271381A1 (en) 2018-01-24
JP2018510871A (ja) 2018-04-19
US20210115104A1 (en) 2021-04-22
PE20180497A1 (es) 2018-03-09
CA2979950A1 (en) 2016-09-22
WO2016146739A1 (en) 2016-09-22
CN107567459B (zh) 2021-09-24

Similar Documents

Publication Publication Date Title
PH12017501674A1 (en) Amylin analogues
SA519401239B1 (ar) نظائر أميلين
WO2015101957A3 (en) Inhibitors of glutaminase
NZ724878A (en) Compounds and compositions as toll-like receptor 7 agonists
MX2016013243A (es) Agonistas peptídicos duales de los receptores de glp-1/glucagón derivados de la exendina-4.
MX2016013248A (es) Agonistas duales del receptor de glp-1/glucagon derivados de exendina-4.
MX2014015423A (es) Analogos de peptido de exedina-4.
MX2018003569A (es) Derivados de acido oleanolico modificado en c4 para la inhibicion de il-17 y otros usos.
PH12016501724A1 (en) Isoindolinone compounds as gpr119 modulators for the treatment of diabetes, obesity, dyslipidemia and related disorders
MX2015015249A (es) Peptidos terapeuticos.
PH12018500315A1 (en) Fumagillol heterocyclic compounds and methods of making and using same
EA033540B1 (ru) Композиция, включающая окру, для применения в уменьшении абсорбции пищевого жира
MX2016013029A (es) Compuestos de indanona sustituidos como modulares de gpr119 para el tratamiento de diabetes, obesidad, dislipidemia y trastornos relacionados.
MX2018002546A (es) Composiciones que comprenden un compuesto de urolitina.
MX2017008196A (es) Composiciones basadas en semillas vegetales y usos de estas.
PH12017500961A1 (en) Spice compositions and uses thereof
MX2016012758A (es) Composicion hiperosmolar de acido hialuronico.
MX2017004760A (es) Formulacion esterilizada por calor que comprende quitosan y proceso para preparacion de la misma.
PH12020550050A1 (en) Novel acylated insulin analogues and uses thereof
MX2019003725A (es) Glicinato de metformina, composiciones farmaceuticas que comprenden la misma, y metodos de uso de la misma.
WO2016038040A3 (en) Dipeptidyl ketoamide compounds and their use for the treatment and/or prevention of fat accumulation
MX2019002647A (es) Composiciones de tesofensina.
PL413830A1 (pl) Kompleks laktoferyny z jonami manganu, sposób jego otrzymywania, zastosowanie kompleksu oraz kompozycja farmaceutyczna zawierająca kompleks laktoferyny i jonów manganu
MX2017007990A (es) Métodos para reducir la agregación plaquetaria y tratar enfermedades cardiovasculares y otros transtornos médicos.
褚妍 Literary Techniques Employed to Develop Celie's Character in The Color Purple